GlySens is a health care and manufacturing startup based in the United States. Founded in 1998, the company is committed to revolutionizing diabetes care with their long-term, implantable continuous glucose monitoring technology. Their flagship product, the Eclipse® ICGM® System, is the world's first truly long-term, wireless, implantable, continuous glucose monitor.
With a $20.00M Series D investment led by Windham Venture Partners in January 04, 2016, GlySens has demonstrated strong investor support. Their vision is to empower individuals with diabetes through worry-free, at-a-glance technologies that provide crucial information for optimizing care, while allowing for a more flexible lifestyle.
GlySens' continuous dedication to pushing the boundaries of diabetes care makes them a compelling venture for potential investors seeking opportunities in the health care and medical device sector.
We care about your data, and we'd love to use cookies make your experience better.